RESHAPE LIFESCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1707 USD | +4.09% |
|
+3.90% | -31.64% |
| Apr. 12 | North American Morning Briefing : Big Banks Kick -2- | DJ |
| Apr. 01 | Transcript : ReShape Lifesciences Inc., Q4 2023 Earnings Call, Apr 01, 2024 |
Financials (USD)
| Sales 2024 * | 9.99M | Sales 2025 * | 11.99M | Capitalization | 3.85M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M | Net income 2025 * | -5M | EV / Sales 2024 * | 0.38 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.32 x |
| P/E ratio 2024 * |
-0.38
x | P/E ratio 2025 * |
-0.47
x | Employees | 29 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on ReShape Lifesciences Inc.
More recommendations
More press releases
| 1 day | +4.09% | ||
| 1 week | +3.90% | ||
| Current month | -7.43% | ||
| 1 month | +4.34% | ||
| 3 months | -28.10% | ||
| 6 months | -41.94% | ||
| Current year | -31.64% |
1 week
0.16
0.18
1 month
0.160.21
Current year
0.140.30
1 year
0.142.99
3 years
0.14475.00
5 years
0.14803.76
10 years
0.141 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 20-01-31 |
| Director of Finance/CFO | 63 | 21-06-14 | |
Dov Gal
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 15-12-31 |
Dan Gladney
CHM | Chairman | 70 | 15-10-31 |
| Director/Board Member | 70 | 21-06-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.1707 | +4.09% | 431,065 |
| 24-04-17 | 0.164 | +1.55% | 272,954 |
| 24-04-16 | 0.1615 | -1.82% | 150,245 |
| 24-04-15 | 0.1645 | -0.13% | 172,425 |
| 24-04-12 | 0.1647 | +0.24% | 199,442 |
Delayed Quote Nasdaq, April 18, 2024 at 04:30 pm EDT
More quotes
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Calendar
2024-05-19
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1707
USD
Average target price
1
USD
Spread / Average Target
+485.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.64% | 3.85M | |
| +2.02% | 209B | |
| +2.17% | 177B | |
| +10.45% | 133B | |
| +16.62% | 99.89B | |
| -2.70% | 61.83B | |
| +13.38% | 52.51B | |
| -6.33% | 45.54B | |
| -4.74% | 39.43B | |
| +9.89% | 38.87B |
- Stock Market
- Equities
- RSLS Stock
